The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > August 29, 2025
Daily News
August 29, 2025
- Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
- Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
- Japan Govt to Spearhead Development of Ultra-Orphan and Infectious Disease Drugs: FY2026 MHLW Budget Request
August 29, 2025
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
- New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- Diagnostics Industry Urges Mechanism to Reflect Rising Costs in Reimbursement
August 29, 2025
- AI in Japanese Pharma: Now, Not Later!
August 29, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…